Glipita-M is the preparation of sitagliptin and metformin. Sitagliptin phosphate, a dipeptidyl peptidase 4(DPP-4) inhibitor and metformin HCI, a member of the biguanide class. Glipita-M is indicated as an adjunct to diet and exercise to treat Type 2 diabetes where metfromin is not enough to improve glycemic control. FDA Approves Glipita-M For Type 2 Diabetes, Offering Powerful Glucose Control Of A DPP-4 Inhibitor And Metformin in a Single Tablet.